Categories: News

SMi�s HPAPI 2019 Conference: Interview with Lonza AG

Interview with Ester Lovsin Barle from Lonza AG who will be speaking at SMi�s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference next month.

London, United Kingdom, April 07, 2019 –(PR.com)– Ester Lovsin Barle from Lonza AG will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. She will be discussing the latest developments in the industry with a specific focus on occupational exposure limits. Ahead of the conference, SMi interviewed her where she gave a taster of what she will be discussing.

Ester said:

“While there seems to be a reduction of new projects from the ‘simple’ small molecule area, there is a very alive and booming field of developing new and imaginative ways to target diseases with new therapeutic applications and modalities, as well as use longstanding highly potent or toxic drugs in new ways. Personally, I find the area of HPAPI very exciting since it is challenging to keep up with the pace of the progress in the field. Challenges are fun!”

“As mentioned before, the progress in the HPAPI field is rapid and there are certain gaps in the knowledge when breaking new grounds. For my professional work as the occupational toxicologist it is a challenge to fill these gaps and protect the safety of the patients and workers in an optimal way despite not knowing it all.”

The full interview is available in the Download Centre on the website.

Key sessions to be discussed in the area of hazard assessment and handling include – Practical elements in rolling out HPAPI projects; Occupational exposure limits; Manufacturing of Oncological Drug Products & Drug Substance by a CDMO; Demonstrating that exposure controls are effective
and OH/containment strategy and NPI at AbbVie

Joining Ester on Day One of the conference will be Mr Justin Mason-Home, Director, HPAPI Project Services Limited; Fabio Zenobi, EHS Director, BSP Pharmaceuticals; Martin Axon, Principal Occupational Hygienist, Safebridge and Olindo Lazzaro, Director, Global EHS Technical Operations, AbbVie.

Sponsors include: BSP Pharmaceuticals | DEC Group | Minakem | PCi Pharma Services | SafeBridge Consultants Inc. | Solo Containment

SMi offer unique sponsorship, exhibition and branding packages, tailored to complement your company’s marketing strategy. Contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: nhoward@smi-online.co.uk

Let’s block ads! (Why?)

Miscw.com

Recent Posts

Capstone Copper Announces 2024 Annual General and Special Meeting Results

VANCOUVER--(BUSINESS WIRE)--Capstone Copper Corp. (“Capstone” or the “Company”) (TSX:CS) (ASX:CSC) announced the voting results from…

10 hours ago

Indonesia International Remittance Market Growth and Future Opportunities 2024-2028: Rising Transaction Values and Volumes Characterize the Landscape – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Indonesia International Remittance Market Business and Investment Opportunities - Analysis by Transaction Value…

10 hours ago

KCAS Bio and Crux Biolabs Announce Global Spectral Flow Cytometry Alliance

KCAS Bio continues to expand its global reach and has selected Crux Biolabs (Melbourne, Australia)…

16 hours ago

Firstsource Acquires Quintessence

Strengthens end-to-end RCM offering to healthcare providers Expands service capabilities to US physicians’ practices, and…

17 hours ago

UPCX Becomes the Main Sponsor for Coinfest Asia 2024

SINGAPORE - Media OutReach Newswire - 3 May 2024 - UPCX (UPC), a developer of…

18 hours ago

China Biological Reagents (Molecular Biology Reagents, Proteins and Cell Reagents) Industry Research 2023-2024 & 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "China Biological Reagents Market (Molecular Biology Reagents, Proteins and Cell Reagents): Insights &…

18 hours ago